We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Tychan

News List

WuXi Biologics Congratulates Tychan on Yellow Fever Antibody Tested Safe and Efficacious in Human Volunteers En-CPhI.CN
November 19, 2019
WuXi Biologics congratulates its partner Tychan on successful completion of the Phase 1A/1B safety and efficacy trials in Singapore for TY014, a first-in-class monoclonal antibody candidate treatment for Yellow Fever (YF).
World's First Candidate Antibody Treatment for Yellow Fever, Developed by Tychan, Tested Safe and Effective in Human Volunteers En-CPhI.CN
November 15, 2019
Tychan's first-in-class monoclonal antibody candidate treatment for Yellow Fever (YF), called TY014, has successfully completed Phase 1A/1B safety trials in Singapore, it announced.
WuXi Biologics Congratulates Tychan on First-in-Class Monoclonal Antibody for Yellow Fever after Record 7 Months of Development en-cphi.cn
December 13, 2018
WuXi Biologics congratulates its partner Tychan for dosing of first individual in phase 1 trial of TY
Tychan Completes Human Safety Studies for Monoclonal Antibody against Zika americanpharmaceuticalreview
October 30, 2018
Tychan has successfully completed Phase-1 safety trials for Tyzivumab, its first-in-class monoclonal antibody (mAb) therapeutic for Zika, in Singapore.